IGMS IGM BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2025, IGM BIOSCIENCES INC reported revenue of n/a, net income of $97.6M and diluted EPS of $1.58; for the fiscal year ended December 2024 revenue was n/a.
IGMS annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$209M, net income −$196M (margin n/a), EPS −$3.24
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$263M, net income −$246M (margin n/a), EPS −$4.71
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$228M, net income −$221M (margin n/a), EPS −$5.32
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$165M, net income −$165M (margin n/a), EPS −$4.93
IGMS quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income $97.6M, EPS $1.58
- Quarter ended Mar 31, 2025: revenue n/a, net income −$52.9M, EPS −$0.86
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$36.6M, EPS −$0.61
- Quarter ended Sep 30, 2024: revenue n/a, net income −$61.4M, EPS −$1.01
- Quarter ended Jun 30, 2024: revenue n/a, net income −$47.9M, EPS −$0.79
- Quarter ended Mar 31, 2024: revenue n/a, net income −$49.8M, EPS −$0.83
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$60.7M, EPS −$0.91
- Quarter ended Sep 30, 2023: revenue n/a, net income −$62.0M, EPS −$1.04
- Quarter ended Jun 30, 2023: revenue n/a, net income −$64.4M, EPS −$1.43
- Quarter ended Mar 31, 2023: revenue n/a, net income −$59.3M, EPS −$1.33
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$52.6M, EPS −$1.14
- Quarter ended Sep 30, 2022: revenue n/a, net income −$58.0M, EPS −$1.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$58.6M, EPS −$1.33
- Quarter ended Mar 31, 2022: revenue n/a, net income −$51.9M, EPS −$1.53
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$50.6M, EPS −$1.50
- Quarter ended Sep 30, 2021: revenue n/a, net income −$44.2M, EPS −$1.32
- Quarter ended Jun 30, 2021: revenue n/a, net income −$38.7M, EPS −$1.16
- Quarter ended Mar 31, 2021: revenue n/a, net income −$31.6M, EPS −$0.95
IGMS cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$153M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$192M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.85M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$125M, share buybacks n/a
IGMS balance sheet
- Jun 30, 2025: cash $30.6M, total assets $107M, total liabilities $6.06M, shareholders' equity $101M
- Mar 31, 2025: cash $36.9M, total assets $207M, total liabilities $206M, shareholders' equity $698K
- Dec 31, 2024: cash $26.5M, total assets $266M, total liabilities $218M, shareholders' equity $48.2M
- Sep 30, 2024: cash $42.9M, total assets $305M, total liabilities $226M, shareholders' equity $78.9M
- Jun 30, 2024: cash $67.0M, total assets $337M, total liabilities $214M, shareholders' equity $122M
- Mar 31, 2024: cash $79.2M, total assets $376M, total liabilities $215M, shareholders' equity $161M
- Dec 31, 2023: cash $113M, total assets $423M, total liabilities $220M, shareholders' equity $203M
- Sep 30, 2023: cash $175M, total assets $474M, total liabilities $220M, shareholders' equity $254M
Is IGMS profitable?
No. IGM BIOSCIENCES INC lost $53.4M over the last four quarters.
What is IGMS's EPS?
Diluted earnings per share over the last four quarters were −$0.90; $1.58 in the latest quarter.